Bernhard Frankenberger

Summary

Affiliation: GSF-National Research Center for Environment and Health
Country: Germany

Publications

  1. ncbi request reprint Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
    Bernhard Frankenberger
    Institute of Molecular Immunology, Forschungszentrum für Umwelt und Gesundheit National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    Clin Cancer Res 11:1733-42. 2005
  2. ncbi request reprint Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells
    Bernhard Frankenberger
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    World J Urol 23:166-74. 2005
  3. doi request reprint Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma
    Alexander Buchner
    Department of Urology, Ludwig Maximilian University of Munich, 81377 Munich, Germany
    Hum Gene Ther 21:285-97. 2010
  4. doi request reprint Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075
    Stefani Spranger
    Institute of Molecular Immunology, German Research Center for Environmental Health, Marchioninistrasse 25, 81377 Munich, Germany
    J Immunol 185:738-47. 2010
  5. pmc Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70
    Anke Zobywalski
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Munich, Germany
    J Transl Med 5:18. 2007
  6. doi request reprint Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity
    Susanne Wilde
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Marchioninistrasse 25, Munich, Germany
    Blood 114:2131-9. 2009
  7. doi request reprint TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
    Stefani Spranger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany
    Blood 119:3440-9. 2012
  8. pmc NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo
    Stefani Spranger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, Marchioninistrasse 25, 81377 Munich, Germany
    J Transl Med 10:30. 2012
  9. doi request reprint Third generation dendritic cell vaccines for tumor immunotherapy
    Bernhard Frankenberger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Marchioninistrasse 25, Munich, Germany
    Eur J Cell Biol 91:53-8. 2012
  10. ncbi request reprint RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis
    Miran Javorovic
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Munich, Germany
    Mol Ther 12:734-43. 2005

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
    Bernhard Frankenberger
    Institute of Molecular Immunology, Forschungszentrum für Umwelt und Gesundheit National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    Clin Cancer Res 11:1733-42. 2005
    ..The effect of these modifications on proliferation, function, and survival of autologous and allogeneic tumor-specific CTLs was assessed...
  2. ncbi request reprint Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells
    Bernhard Frankenberger
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    World J Urol 23:166-74. 2005
    ....
  3. doi request reprint Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma
    Alexander Buchner
    Department of Urology, Ludwig Maximilian University of Munich, 81377 Munich, Germany
    Hum Gene Ther 21:285-97. 2010
    ..These results suggest that this vaccine could be useful in combination therapies and/or minimal residual disease...
  4. doi request reprint Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075
    Stefani Spranger
    Institute of Molecular Immunology, German Research Center for Environmental Health, Marchioninistrasse 25, 81377 Munich, Germany
    J Immunol 185:738-47. 2010
    ..Thereby, mature DCs prepared within 3 d using such maturation mixtures displayed optimal functions required for vaccine development...
  5. pmc Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70
    Anke Zobywalski
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Munich, Germany
    J Transl Med 5:18. 2007
    ..We therefore developed new maturation cocktails allowing DCs to produce biologically active IL-12p70 for large-scale cancer vaccine development...
  6. doi request reprint Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity
    Susanne Wilde
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Marchioninistrasse 25, Munich, Germany
    Blood 114:2131-9. 2009
    ..This approach allows high-avidity T cells and TCR specific for tumor-associated self-peptides to be easily obtained for direct adoptive T-cell therapy or for isolation of therapeutic transgenic TCR sequences...
  7. doi request reprint TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
    Stefani Spranger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany
    Blood 119:3440-9. 2012
    ..Our findings clearly limit the use of HMMR-TCR therapy to MHC- mismatched HSC transplantation, in which HLA-A2 differences can be used to restrict recognition to patient HSCs and leukemia...
  8. pmc NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo
    Stefani Spranger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, Marchioninistrasse 25, 81377 Munich, Germany
    J Transl Med 10:30. 2012
    ..This led to selection of a simple and rapid protocol for engraftment and vaccine evaluation that encompassed 4 weeks...
  9. doi request reprint Third generation dendritic cell vaccines for tumor immunotherapy
    Bernhard Frankenberger
    Institute of Molecular Immunology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Marchioninistrasse 25, Munich, Germany
    Eur J Cell Biol 91:53-8. 2012
    ....
  10. ncbi request reprint RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis
    Miran Javorovic
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Munich, Germany
    Mol Ther 12:734-43. 2005
    ....
  11. doi request reprint Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition
    Susanne Wilde
    Institute of Molecular Immunology, Helmholtz Center Munich, German
    J Immunol 189:598-605. 2012
    ..Thus, Th1 polycytokine secretion served as a suitable parameter to rapidly demark cytotoxic CD8(+) T cell clones for further TCR evaluation...
  12. ncbi request reprint Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies
    Ingrid G Schuster
    Institute of Molecular Immunology, Forschungszeutrum für Umwelt und Gesundheit GSF National Research Center for Environment and Health, Munich, Germany
    Blood 110:2931-9. 2007
    ..Allorestricted TCRs with specificity for naturally presented FMNL1-derived epitopes may represent promising reagents for the development of adoptive therapies in lymphoma and other malignant diseases...
  13. pmc Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation
    Maja Bürdek
    German Research Center for Environmental Health, Institute of Molecular Immunology, Marchioninistr, 25, 81377 Munchen, Germany
    J Transl Med 8:90. 2010
    ....
  14. doi request reprint Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
    Kathleen Ebelt
    Institute of Molecular Immunology, Clinical Cooperation Group Immune Monitoring, Helmholtz Center Munich, German Research Center for Environmental Health, Marchioninistr 25, Munich 81377, Germany
    Eur J Cancer 45:1664-72. 2009
    ..Expression of molecules associated with inhibition and exhaustion of lymphocytes may reflect events contributing to ineffective immune responses against cancer cells...
  15. ncbi request reprint Immune suppression in renal cell carcinoma
    Bernhard Frankenberger
    Institute of Molecular Immunology, GSF National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    Semin Cancer Biol 17:330-43. 2007
    ..Understanding these complex host-tumor interactions has broad implications for successful application of cytokine therapy and other forms of immunotherapy for RCC...
  16. ncbi request reprint Activated B cells mediate efficient expansion of rare antigen-specific T cells
    Caroline Zentz
    Clinical Cooperative Group Molecular Oncology, GSF National Research Center for Environment and Health, Munich, Germany
    Hum Immunol 68:75-85. 2007
    ..These results strongly encourage the use of CD40-stimulated B cells as APCs in immunotherapy...
  17. ncbi request reprint Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response
    Valeria Milani
    Clinical Cooperation Group of Hyperthermia, Internal Medicine Department III, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany
    Int Immunol 17:257-68. 2005
    ..Moreover, these results document the maintenance of immunological homeostasis during recovery from heat treatment, thus challenging the view that tumor cells subjected to heat shock become resistant to CTL recognition...